Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in RA with High IFN Signature
NCT03435601Phase 2Unknown
- Start
- Apr 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anifrolumab in rheumatoid arthritis (RA). Status: unknown.
02
Drugs
anifrolumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03435601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435601.